Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97499 | 0.94 | CYP1A2 (0.50) | CYP1A2NAAA | |
| SCHEMBL97842 | 0.78 | CYP1A2 (0.47) | CYP1A2NAAASIGMAR1EPHX1CCR2 | |
| SCHEMBL8629299 | 0.77 | HTT (0.40) | CYP1A2NAAAEPHX1 | |
| SCHEMBL8629303 | 0.77 | HTT (0.40) | CYP1A2NAAAEPHX1 | |
| SCHEMBL7769924 | 0.75 | CYP1A2 (0.65) | CYP1A2NAAASIGMAR1EPHX1CCR2 | |
| SCHEMBL28117111 | 0.74 | CYP1A2 (0.65) | CYP1A2NAAASIGMAR1EPHX1CCR2 | |
| SCHEMBL25394046 | 0.73 | CYP1A2 (0.85) | CYP1A2NAAASIGMAR1EPHX1 | |
| SCHEMBL7733130 | 0.73 | CYP1A2 (0.85) | CYP1A2NAAASIGMAR1EPHX1 | |
| SCHEMBL29076360 | 0.73 | CYP1A2 (0.85) | CYP1A2NAAASIGMAR1EPHX1 | |
| SCHEMBL133028 | 0.73 | CYP1A2 (0.85) | CYP1A2NAAASIGMAR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | CYP1A2 3062/4885NAAA 4652/4885SIGMAR1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.